Journal article

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J Solomon, Alice T Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D Wilner, Tony Mok

CANCER RESEARCH AND TREATMENT | KOREAN CANCER ASSOCIATION | Published : 2018

Abstract

Purpose: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. Materials and Methods: This analysis evaluated previously treated and untreated patients in two randomized, openlabel phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intent..

View full abstract

Grants

Funding Acknowledgements

This work was supported by Pfizer Inc. We would like to thank all of the participating patients and their families, as well as the investigators, research nurses, study coordinators, and operations staff, along with Hironori Kikkawa (Pfizer, Japan) for providing the analyses for this publication. The studies included in this analysis were sponsored by Pfizer Inc. Medical writing and editorial support were provided by Jade Drummond and Simon Lancaster of inScience Communications, Springer Healthcare (Chester, UK), and were funded by Pfizer Inc.